Sponsor content
866 result(s) found, displaying 321 to 330
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., 29/01/2023
-
Prescription medicine registrationActive ingredients: Rivaroxaban.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CIPLOTINIB erlotinib (as hydrochloride) 25 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CIPLOTINIB erlotinib (as hydrochloride) 150 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ERLOCIP erlotinib (as hydrochloride) 25 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ERLOTINIB CIPLA erlotinib (as hydrochloride) 100 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ERLOCIP erlotinib (as hydrochloride) 100 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ERLOCIP erlotinib (as hydrochloride) 150 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CIPLOTINIB erlotinib (as hydrochloride) 100 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ERLOTINIB CIPLA erlotinib (as hydrochloride) 150 mg tablet blister pack.